Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Thus, BAY 80-6946 induced 100% complete tumor regression when dosed as a single agent every second day in rats bearing HER2-amplified and PIK3CA-mutated KPL4 breast tumors.
|
24170767 |
2013 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our findings were substantiated in a cohort of breast tumors in which IGF-1R expression was positively correlated with ERα/Src and ERα/PI3K expression, hallmarks of nongenomic estrogen signaling, reinforcing the link between IGF-1R and mERα.
|
30692633 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
This review focuses on two major pathways that have recently emerged as important opportunities for therapeutic intervention in endocrine resistant breast tumors: PI3K/AKT/mTOR cell signaling and cyclinD1/cyclin-dependent kinase 4/6 cell cycle pathways.
|
29719270 |
2018 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
AR levels were significantly higher in breast tumors with kinase domain PIK3CA mutations versus tumors that are wild type or with PIK3CA helical mutations (P = 0.017 and P < 0.0001, respectively).
|
19276248 |
2009 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Human epidermal growth factor receptor-2 (HER2) amplification/overexpression (HER2+) frequently co-occurs with PI3K pathway activation in breast tumors.
|
26500061 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This provides a rationale for the combined targeting of p110α with IGF1R or p110β in patients with breast tumors harboring PIK3CA mutations.
|
27048245 |
2016 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages.
|
29880805 |
2018 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
However, here we show through phosphoprotein profiling and functional genomic studies that many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth.
|
19573809 |
2009 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
For example, although signaling and metabolic profiles of breast tumors with PIK3CA or AKT1 mutations are, as expected, highly similar, they display markedly different, sometimes even opposite, profiles to those with ERBB2 or EGFR amplifications.
|
24166508 |
2014 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, we found that VEGF-A 165 (recombinant protein or breast tumor cell-secreted) is also capable of inducing migration of VEGFR2-negative human aortic smooth muscle cells (hAOSMCs), and this induction is mediated through a molecular cross-talk of neuropilin-1 (NRP-1), VEGFR1 (Flt-1), and phosphoinositide 3-kinase (PI3K)/Akt signaling kinase.
|
18284215 |
2008 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
These data suggest that activation of the ERBB2-PI3K-AKT pathway by loss of PTEN at early stages of tumorigenesis promotes the formation of breast tumors with apocrine features.
|
20712882 |
2010 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
|
20479250 |
2010 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
PIK3CA mutations are not associated with altered sensitivity to preoperative anthracycline-based or taxane-based chemotherapies in ER-positive and ER-negative breast tumors.
|
18371219 |
2008 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In this study, we present an integrated genomic analysis based on the use of a PI3K gene expression signature as a framework to analyze orthogonal genomic data from human breast tumors, including RNA expression, DNA copy number alterations, and protein expression.
|
28176176 |
2017 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In comparing deregulation of oncogenic pathways between age groups, a higher probability of PI3K (p = 0.006) and Myc (p = 0.03) pathway deregulation was observed in breast tumors arising in younger women.
|
18167534 |
2008 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We showed that hyperphosphorylation in ATP citrate lyase (ACL) occurs frequently in human breast tumors and correlates well with HER2+ and/or PIK3CA-mutant (HER2+/PIK3CAmut) status in breast tumor cell lines.
|
27015560 |
2016 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Treatment of clinical breast tumors with the antiendocrine drug fulvestrant resulted in increased ErbB3 expression and PI3K/mTOR signaling.
|
23999432 |
2013 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
|
19685490 |
2010 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Twenty-three (27%) of the 86 primary breast tumors contained PIK3CA mutations.
|
23184205 |
2012 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph node metastasis and poor survival.
|
22033276 |
2011 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In pre-clinical models, co-existence of Human Epidermal Growth Factor Receptor-2 (HER2)-amplification and PI3K catalytic subunit (PIK3CA) mutations results in aggressive, anti-HER2 therapy-resistant breast tumors.
|
31219154 |
2019 |
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
|
21558396 |
2011 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
We found that activation of the latent Pik3ca(H1047R) allele resulted in breast tumors with multiple histological types.
|
22370636 |
2013 |
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
|
15647370 |
2005 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Additionally, associations were found for EGFR variations in lung tumors and PIK3CA variations in breast tumors.
|
31100334 |
2019 |